For around three decades, the fluoroquinolone (FQ) antibiotic ciprofloxacin has been used
to treat a range of diseases, including chronic otorrhea, endocarditis, lower respiratory tract …

The lack of effective treatments for pulmonary diseases presents a significant global health
burden, primarily due to the challenges posed by the pulmonary barrier that hinders drug …

In the 50 years following the introduction of the first dry powder inhaler to the market, several
developments have occurred. Multiple-unit dose and multi-dose devices have been …

Respiratory infections represent a major global health problem. They are often treated by
parenteral administrations of antimicrobials. Unfortunately, systemic therapies of high-dose …

Dry powder inhaler (DPI) products have traditionally comprised a simple formulation of
micronised drug mixed with a carrier excipient, typically lactose monohydrate. The presence …

Dry powder inhalers (DPIs) can be used with a wide range of drugs such as small molecules
and biologics and offer several advantages for inhaled therapy. Early DPI products were …

Gram-negative organisms comprise a large portion of the pathogens responsible for lower
respiratory tract infections, especially those that are nosocomially acquired, and the rate of …

Current pulmonary treatments against Pseudomonas aeruginosa infections in cystic fibrosis
(CF) lung suffer from deactivation of the drug and immobilization in thick and viscous …

Cystic fibrosis (CF) is the most common autosomal recessive disease in Caucasians
associated with early death. Although the faulty gene is expressed in epithelia throughout …

Cystic fibrosis (CF) is a genetic disease affecting today nearly 70,000 patients worldwide
and characterized by a hypersecretion of thick mucus difficult to clear arising from the …